

Rationale Therapie des kastrationsresistenten Prostatakarzinoms

Jennifer Kranz, Matthias Saar

Literatur

1. Clarke NW et al. Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC) [ASCO GU abstract LBA16]. *J Clin Oncol* 2023; 41(6)
2. Smith MR et al. SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med* 2018; 378(15):1408–18
3. Sternberg CN et al. PROSPER Investigators. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*; 382(23): 2197–206
4. Fizazi K et al. ARAMIS Investigators. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med* 2019; 380(13): 1235–46
5. Oudard S et al. Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a post hoc analysis of the SPARTAN phase III trial. *ASCO GU* 2023
6. Tannock IF et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004; 351(15): 1502–12
7. de Bono JS et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet* 2010; 376(9747): 1147–54
8. de Bono JS et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011; 364(21): 1995–2005
9. Scher HI et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012; 367(13): 1187–97
10. Beer TM et al. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014; 371(5): 424–33
11. Ryan CJ et al. COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013; 368(2): 138–48
12. Parker C et al. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013; 369(3): 213–23

13. Sartor O et al. VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med* 2021; 385(12): 1091–103
14. de Bono J et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med* 2020; 382(22): 2091–102
15. S3-Leitlinie Prostatakarzinom. AWMF-Registernummer: 943/022OL. (https://register.awmf.org/assets/guidelines/043-022OL1_S3_Prostatakarzinom_2021-10.pdf). Zugegriffen: 11.05.2023
16. Bryce AH et al. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy [ASCO GU abstract 18]. *J Clin Oncol* 2023; 41(6)
17. Lang SH et al. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. *Int J Oncol* 2019; 55(3): 597–616
18. de Bono JS et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. *Annals of Oncology* 2019; 30(5): v325–v55
19. Schiewer MJ et al. Dual roles of PARP-1 promote cancer growth and progression. *Cancer Discov* 2012; 2(12): 1134–49
20. Polkinghorn WR et al. Androgen receptor signaling regulates DNA repair in prostate cancers. *Cancer Discov* 2013; 3(11): 1245–53
21. Agarwal N et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [ASCO GU abstract LBA17]. *J Clin Oncol* 2023; 41(6)